CICLOPIROX
LOE ApproachingNDATOPICALGEL
Approved
Jul 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
CICLOPIROX by Alvogen is clinical pharmacology mechanism of action ciclopirox is a hydroxypyridone antifungal agent that acts by chelation of polyvalent cations (fe or al), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell. First approved in 1997.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ciclopirox is a topical antifungal gel approved in 1997 for treating onychomycosis and dermatomycoses. It works by chelating polyvalent cations (Fe or Al) to inhibit metal-dependent enzymes responsible for peroxide degradation in fungal cells. The drug is applied topically with minimal systemic absorption (<5% of applied dose).
LOE Approaching
Product is in late-stage maturity with declining market position relative to newer competitors; brand team likely operates with lean staffing focused on cost management and market retention.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Ciclopirox is a hydroxypyridone antifungal agent that acts by chelation of polyvalent cations (Fe or Al), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CICLOPIROX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.